Astellas Pharma Gmbh

Yamanouchi Pharmaceutical Company Ltd.

Helix Research Institute

Masazumi Kamohara

Jun Takasaki

Tetsu Saito

Mitsuyuki Matsumoto

Masato Kobayashi

Toru Sugimoto

Yoshinori Ishii

Shigenori Yagi

Takao Isogai

Tetsuo Nishikawa

Toshio Ota

Takatoshi Soga

Hirotsugu Tanaka

Takahide Ohishi

Atsuo Yonezawa

Eiji Yoshimi

Yuri Kawai

Yukari Koya

Tohru Sugimoto

Hiromi Nara

Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.

Anti-human tie-2 antibody

Anti-human NGF antibodies are useful for treating pain.

Method of treating pain with anti-human NGF antibody

[Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab' fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

Anti-human NGF antibody

The invention relates to a convenient screening tool for identifying an agent for treating diabetes. The screening tool is a G protein-coupled receptor, a variant of the G protein-coupled receptor, or a homolog of the G protein-coupled receptor, which promotes insulin secretion under a high glucose concentration by activation. The invention also relates to cells transformed with an expression vector comprising a polynucleotide encoding and expressing the screening tool. The invention provides a convenient screening method for identifying an agent for treating diabetes, pharmaceutical compositions comprising the agent, and a process for manufacturing the pharmaceutical composition.

Method for screening agents for the treatment of diabetes

A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2Tprotein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2Tligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.

Method of screening antiplatelet agents

This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.

Polynucleotides encoding SREB1 receptor

A cDNA encoding a novel LTCreceptor has been isolated. Provision of the novel protein, an LTCreceptor, enabled binding experiments using the LTC. By screening for compounds that modulate LTCreceptor activity based on these binding experiments, development of drugs targeting the LTCreceptor becomes possible.

Peptide leukotriene receptor

Polynucleotides encoding SREB3 receptor

This invention belongs to the genetic engineering field, and provides the novel G protein-coupled receptor family protein SREB2 expressed in the central nervous system, genes coding for the protein, screening methods using the protein and so on. As one of the methods for obtaining the G protein-coupled receptor protein of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.

Polynucleotides encoding SRE B2 receptor

Growing community of inventors

Ibaraki, Japan

Masazumi Kamohara